The evaluation of Aslem efficacy on post- operative survival duration of 164 patients with primary liver cancer treated in Viet Duc Hospital during 1991-2000 year period showed the supporting effect of Aslem after surgery, it improved dramatically the post operative survival duration of patients, especially in the group of removing liver lesions in combining with aslem in yield directly into the tumor
Adjuvants, Immunologic ; Therapeutics ; Liver Neoplasms

M capsules are applied to treat NPC after radiotherapy. In comparision with 28 NPC patients who are do not use M capsules we have some remarks: the number of white blood cells, lymphocytes and lymphocyte subset increase faster and remain more stable, and there is a decrease of IgA/VCA titre lower and more stable in patients who used M capsules in comparision with those in the control group. In the using M capsules group we find that the number of patients who survive over three years increase as well as the metastasis rate. This result shows that M capsule might have effecting rising the number of white blood cells in NPC patients who got treated radiotherapy, and help lasting the life of the NPC patients.
Radiotherapy ; Blood Cells ; Adjuvants, Immunologic ; neoplasms

In order to enhance the capability of antiserum production rabbits, Mycobacterium vaccae was used to stimulate rabbit’s immune system unspecifically before immunization with Haemophilus influenzae type b (Hib). The results showed that only single immunization with Hib antigen: the number of rabbits had response fulfill depended-time requirements (harvested after 1 or 6 months) varied from 30% to 70%, harvesting time for antiserum with fulfilled quantity and quality was 24 weeks (6 months) (2 courses induced immunization). Stimulating rabbit’s immune system by M. vaccae, then inducing rabbit’s immunization with Hib antigen: the number of rabbits had response fulfiling requirements varied from 71.4% to 100%; harvesting time for antiserum with fulfilled quantity and quality was 5 weeks (only after 1 course induced immunization). Sensitivity and specificity of antiserum were unchanged
Mycobacterium ; Helicobacter pylori ; Immune Sera ; Adjuvants, Immunologic

With the imminent and widespread ban of the use of antibiotic feed additives and chemical antimicrobials in food production animals, alternative measures need to be sought to ensure that the livestock industry will not be adversely affected. Cytokines are proteins that control the type and extent of an immune response following infection or vaccination. They therefore represent excellent naturally occurring therapeutics. The identification, cloning and characterisation of cytokine genes in chickens have lagged somewhat behind similar work in mammals. Progress in isolating chicken homologues of mammalian cytokines has also been slowed by the generally low level of sequence similarity. Chicken cytokine genes that have been cloned to date include ChIFN-gamma, ChIL-1beta, ChIFN-alpha, ChIL-15, ChIL-18, ChIL-8, ChIL-2, ChIL-6, ChIL-16, SCF, MGF, TGFbeta, Lymphotactin, MIP-1beta, CXC and CC chemokines, so the use of cytokines in poultry has become more feasible with the discovery of a number of avian cytokine genes. The delivery methods for chicken cytokine are of prime importance and are required to be safe, easy to administer and cost-effective. Live viral vectors such as fowl adenovirus (FAV) expressing cytokine genes can be delivered via drinking water or aerosol sprays, making it very easy to administer. Since the immune system of chickens is similar to that of mammals, they offer an attractive model system to study the effectiveness of cytokine therapy in the control of disease in livestock. This review focus on the recent advances made in avian cytokines, with a particular focus on their assessment as therapeutic agents and vaccine adjuvants.
Adjuvants, Immunologic ; metabolism ; Animals ; Cytokines ; genetics ; immunology ; metabolism ; Immunotherapy ; methods

Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) expressed in a wide spectrum of cell types that recognize distinctive ligands and subsequently activate adaptive immune responses. TLR ligands are considered a promising target for development of immunomodulatory agents. Extensive clinical investigations are currently underway to develop TLR ligands-based non-specific immunostimulants and vaccine adjuvants. It has been well accepted that cancer cells develop a strategy to avoid host immune responses by producing inhibitory molecules. In addition, tumor-associated antigens are often not strong enough to induce effective anti-cancer immune responses. In this context, immunostimulants or adjuvants are critically required for more effective cancer immunotherapies. Here, we discuss recent progresses in the field of cancer immunotherapy under special emphasis on the TLR ligands as a component of immunostimulatory agents.
Adjuvants, Immunologic ; Immunotherapy ; Ligands ; Receptors, Pattern Recognition ; Toll-Like Receptors

Adjuvants can be defined as pharmacological and immunological components that are able to modify and/or enhance antigen-specific immune responses. Based on the interdisciplinary research between immunology and material science/engineering, various vaccine adjuvant materials have been developed. By rational design and engineering of antigen or adjuvant materials, immune-modulatory vaccine systems generated to activate immune system. Here, we review the current progress of bioengineered prophylactic and/or therapeutic vaccine adjuvant for cancer and/or infectious disease, and discuss the prospect of future vaccine adjuvant materials.
Adjuvants, Immunologic ; Allergy and Immunology ; Communicable Diseases* ; Immune System ; Immunomodulation ; Immunotherapy*

In recent years, the development of new vaccines such as nucleic acid vaccines, genetically engineered vaccines, and synthetic peptide vaccines has achieved rapid development. However, compared with traditional inactivated or live vaccines, these vaccines often have problems such as poor immunogenicity. Therefore, an adjuvant is needed to enhance its effect, and adjuvants have proven to be a key component in vaccines. There are many types of adjuvants, while currently no unified standard for the classification. At present, the most commonly used adjuvants are Aluminum adjuvant and Freund's adjuvant, but new generation vaccines will probably need new generation adjuvants. Thus, this review aims to showcase the current status of immune adjuvants, with the focus on immunomodulatory molecular adjuvant, antigen delivery adjuvant and compound adjuvant. This review provides new insights for the development of novel vaccine adjuvants.
Adjuvants, Immunologic/pharmacology* ; Freund's Adjuvant ; Vaccines ; Vaccines, Subunit

Vaccination is an effective method for preventing influenza, and adjuvants can enhance the immune response intensity and persistence of influenza vaccines. However, there are currently shortcomings in clinical adjuvant approvals, ineffectiveness against weak antigens, and a tendency to cause headaches. Therefore, the development of safe and effective novel adjuvants for influenza vaccines is particularly important to enhance vaccine immunogenicity and safety. Given the wide range of sources, high safety, and biodegradability of traditional Chinese medicine(TCM), some studies have described it as a vaccine adjuvant. This article reviewed the current status and challenges of influenza vaccine adjuvants, summarized the types of TCM adjuvants, the safety and immunomodulatory effects of natural active ingredients from TCM combined with influenza vaccines, the role of TCM adjuvants in antigen storage, antigen presentation capability, immune cells and cytokines, and immune responses, and analyzed the advantages and disadvantages of TCM adjuvants compared with small molecule adjuvants, with the aim of promoting the clinical development and commercialization of TCM adjuvants for influenza vaccines.
Humans ; Influenza Vaccines ; Adjuvants, Immunologic/pharmacology* ; Medicine, Chinese Traditional ; Influenza, Human/prevention & control* ; Adjuvants, Pharmaceutic

Preparation of high quality allergen extracts is essential for the diagnosis and immunotherapy of allergic disorders. Standardization of allergen extracts concerns determination of the allergen unit, development of reference material and measurement of the overall IgE binding capacity of an allergen extract. Recently, quantification of individual allergens has been the main focus of allergen standardization because the allergenicity of most allergen extracts is known to be mainly dependent on the content of a small number of allergen molecules. Therefore, characterization of major allergens will facilitate the standardization of allergens. In this article, we review the current state of allergen standardization. In addition, we briefly summarize the components of allergen extracts that should be under control for the optimization of allergen standardization, since its adjuvant-like activities could play an important role in allergic reactions even though the molecule itself does not bind to the IgE antibodies from subjects.
Adjuvants, Immunologic/chemistry ; Allergens/chemistry/*immunology/isolation & purification ; Polymorphism, Genetic ; Reference Standards ; Republic of Korea

Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.
Adaptive Immunity ; Adjuvants, Immunologic ; Communicable Diseases* ; Humans ; Immunity, Innate ; Vaccine Potency ; Vaccines